. . . . . . . . . . . . "[Many of these advances originated from studies of the genetic disease tuberous sclerosis complex (TSC), leading to one of the clearest therapeutic opportunities to target mTOR with rapamycin and its analogs ('rapalogs'), which effectively inhibit mTOR complex 1 (mTORC1) by an allosteric mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2015-02-27"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2015-08-25T14:41:39+02:00"^^ . . . . . . . . . . . "v3.0.0.0" . "v3.0.0" .